Gill D - Search Results

1

Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases.

Tate JR, Mollee P, Dimeski G, Carter AC, Gill D. Tate JR, et al. Among authors: gill d. Clin Chim Acta. 2007 Feb;376(1-2):30-6. doi: 10.1016/j.cca.2006.07.011. Epub 2006 Jul 14. Clin Chim Acta. 2007. PMID: 16945362

2

Practical considerations for the measurement of free light chains in serum.

Tate JR, Gill D, Cobcroft R, Hickman PE. Tate JR, et al. Among authors: gill d. Clin Chem. 2003 Aug;49(8):1252-7. doi: 10.1373/49.8.1252. Clin Chem. 2003. PMID: 12881439 Review.

3

Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis.

Morris KL, Tate JR, Gill D, Kennedy G, Wellwood J, Marlton P, Bird R, Mills AK, Mollee P. Morris KL, et al. Among authors: gill d. Intern Med J. 2007 Jul;37(7):456-63. doi: 10.1111/j.1445-5994.2007.01368.x. Intern Med J. 2007. PMID: 17547724 Clinical Trial.

4

The reporting of serum protein electrophoresis to clinicians.

Tate JR, Mollee P, Gill D. Tate JR, et al. Among authors: gill d. Clin Chim Acta. 2005 Aug;358(1-2):204-5. doi: 10.1016/j.cccn.2005.04.010. Clin Chim Acta. 2005. PMID: 15946659 No abstract available.

5

Significance of abnormal protein bands in patients with multiple myeloma following autologous stem cell transplantation.

Hall SL, Tate J, Gill D, Mollee P. Hall SL, et al. Among authors: gill d. Clin Biochem Rev. 2009 Aug;30(3):113-8. Clin Biochem Rev. 2009. PMID: 19841693 Free PMC article.

6

Serum free light chains for monitoring multiple myeloma.

Tate J, Mollee P, Gill D. Tate J, et al. Among authors: gill d. Br J Haematol. 2005 Feb;128(3):405-6; author reply 406-7. doi: 10.1111/j.1365-2141.2004.05338.x. Br J Haematol. 2005. PMID: 15667546 Free article. No abstract available.

7

Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.

Taylor E, Jones M, Hourigan MJ, Johnson DW, Gill DS, Isbel N, Hawley CM, Marlton P, Gandhi MK, Campbell SB, Mollee P. Taylor E, et al. Nephrol Dial Transplant. 2015 Oct;30(10):1774-9. doi: 10.1093/ndt/gfv260. Epub 2015 Jul 18. Nephrol Dial Transplant. 2015. PMID: 26188340

8

Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma.

Gandhi MK, Lambley E, Burrows J, Dua U, Elliott S, Shaw PJ, Prince HM, Wolf M, Clarke K, Underhill C, Mills T, Mollee P, Gill D, Marlton P, Seymour JF, Khanna R. Gandhi MK, et al. Among authors: gill d. Clin Cancer Res. 2006 Jan 15;12(2):460-4. doi: 10.1158/1078-0432.CCR-05-2008. Clin Cancer Res. 2006. PMID: 16428487

9

The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization.

Keane C, Gibbs S, Seymour JF, Mills AK, Grimmett K, Van Kuilenberg R, Saal R, Gill D, Prince HM, Marlton P, Mollee P. Keane C, et al. Among authors: gill d. Hematol Oncol. 2006 Sep;24(3):159-63. doi: 10.1002/hon.784. Hematol Oncol. 2006. PMID: 16775841

10

Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.

Lane SW, Crawford J, Kenealy M, Cull G, Seymour JF, Prince HM, Marlton P, Gill D, Mollee PN. Lane SW, et al. Among authors: gill d. Leuk Lymphoma. 2006 Sep;47(9):1813-7. doi: 10.1080/10428190600632832. Leuk Lymphoma. 2006. PMID: 17064993

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,925 results

Search Page

Filters